AtaiBeckley CEO Executes Massive Insider Buy‑Back, Buying 42,579 Shares Amid Psychedelic Surge and FDA Optimism
Insider buys reveal strong confidence in AtaiBeckley’s psychedelic drug pipeline—up to 300% ownership increase amid market gains and FDA‑friendly news.
2 minutes to read